Serum CD44 splice variants in cervical cancer patients.

No abstract is available for this paper.

• Publication year

  1995

• Venue

  Cancer Letters

• Publication date

  1995-04-14

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/0304-3835(95)03708-5PMID 7537626
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Serum CD44 in malignant lymphoma: an association with treatment response.

  1994cited by this paper
• The two major CD44 proteins expressed on a metastatic rat tumor cell line are derived from different splice variants: each one individually suffices to confer metastatic behavior.

  1993cited by this paper
• Lymphocyte homing receptor (CD44) expression is associated with poor prognosis in gastrointestinal lymphoma.

  1993cited by this paper
• Expression of CD44 variant proteins in human colorectal cancer is related to tumor progression.

  1993cited by this paper
• Glycoprotein CD44 expression and its association with survival in breast cancer.

  1993cited by this paper
• A human homologue of the rat metastasis-associated variant of CD44 is expressed in colorectal carcinomas and adenomatous polyps

  1993cited by this paper
• Expression of CD44R1 adhesion molecule in colon carcinomas and metastases.

  1993cited by this paper
• A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells.

  1991cited by this paper
• Alternative splicing in the control of gene expression.

  1989cited by this paper
• An evaluation of squamous cell carcinoma antigen in patients with cervical squamous cell carcinoma.

  1987cited by this paper
• A distinct endothelial cell recognition system that controls lymphocyte traffic into inflamed synovium.

  1986cited by this paper

• Single-cell and bulk transcriptome profiling reveals RNA-binding protein regulatory programs in cervical cancer

  2025cites this paper
• Digging into the Solubility Factor in Cancer Diagnosis: A Case of Soluble CD44 Protein

  2025cites this paper
• Spatial-Division Multiplexing Approach for Simultaneous Detection of Fiber-Optic Ball Resonator Sensors: Applications for Refractometers and Biosensors

  2022cites this paper
• Label-free fiber-optic spherical tip biosensor to enable picomolar-level detection of CD44 protein

  2021cites this paper
• Immunohistochemical Expression and Serum Levels of CD44 as Prognostic Indicators in Patients with Non-Small Cell Lung Cancer

  2016cites this paper
• Evaluation of CD44 and CD44v6 in Colorectal Carcinoma Patients: Soluble Forms in Relation to Tumor Tissue Expression and Metastasis

  2008cites this paper
• Soluble CD44 secretion contributes to the acquisition of aggressive tumor phenotype in human colon cancer cells.

  2007cites this paper
• HAS3-related hyaluronan enhances biological activities necessary for metastasis of osteosarcoma cells.

  2006cites this paper
• Renal expression of CD44 correlates with acute renal allograft rejection.

  2006cites this paper
• Are serum levels of CD44 relevant in children with pediatric sarcomas?

  2006cites this paper
• Pre-transplant plasma and cellular levels of CD44 correlate with acute renal allograft rejection.

  2005cites this paper
• Soluble CD44 v5 and v6 in serum of patients with breast cancer. Correlation with expression of CD44 v5 and v6 variants in primary tumors and location of distant metastasis

  2004cites this paper
• Concentration of soluble CD44 standard and soluble CD44 variant V5 in the serum of patients with malignant bone tumors.

  2003cites this paper
• Predictive relevance of soluble CD44v6 serum levels for the responsiveness to second line hormone- or chemotherapy in patients with metastatic breast cancer.

  2001cites this paper
• Serum CD44 Levels Preceding the Diagnosis of Non-Hodgkin's Lymphoma

  2000cites this paper
• CD44 expression in soft tissue sarcomas

  2000cites this paper
• Evaluation of the prognostic value of serum soluble CD 44 in patients with breast cancer.

  1999cites this paper
• Evaluation of soluble CD44v6 as a potential serum marker for head and neck squamous cell carcinoma.

  1999cites this paper
• The serum assay of soluble CD44 standard (sCD44-st), CD44 splice variant 5 (sCD44-v5), and CD44 splice variant 6 (sCD44-v6) in patients with cervical cancer.

  1998cites this paper
• CD31 expression in benign, borderline, and malignant epithelial ovarian tumors: an immunohistochemical and serological analysis.

  1998cites this paper
• Clinical significance of serum levels of CD44 variant exons 8–10 protein in colorectal cancer

  1998cites this paper
• Soluble adhesion molecules in serum and cyst fluid from patients with cystic tumours of the ovary.

  1998cites this paper
• Serum assay of soluble CD44 standard (sCD44-st), CD44 splice variant v5 (sCD44-v5), and CD44 splice variant v6 (sCD44-v6) in patients with epithelial ovarian cancer.

  1997cites this paper
• Low serum levels of soluble CD44 variant 6 are significantly associated with poor prognosis in patients with pancreatic carcinoma

  1997cites this paper
• Serum CD44 levels in patients with non-small cell lung cancer and their relationship with clinicopathological features.

  1997cites this paper
• CD44 is an independent prognostic factor in early‐stage cervical cancer

  1997cites this paper
• Soluble CD44 variants in the serum of patients with urological malignancies.

  1997cites this paper
• Soluble CD44 molecules in serum of patients with prostate cancer and benign prostatic hyperplasia.

  1996cites this paper
• Serological Evaluation of Soluble CD44 in Renal Cancer

  1996cites this paper
• A New Alternatively Spliced Exon between v9 and v10 Provides a Molecular Basis for Synthesis of Soluble CD44*

  1996cites this paper
• Soluble CD44 Molecules in Serum of Patients with Cancer and Benign Prostatic Hyperplasia Prostate

  1996cites this paper
• Immunohistochemical and serological evaluation of CD44 splice variants in human ovarian cancer.

  1995cites this paper